Tyra biosciences reports third quarter 2024 financial results and highlights

- reported positive interim clinical proof-of-concept results for tyra-300 in muc from surf301 ph1/2 study - - ind cleared for phase 2 study of tyra-300 in pediatric achondroplasia (beach301) - - strengthened leadership with appointment of doug warner, md as chief medical officer - - cash, cash equivalents, and marketable securities of $360.1 million at q3 2024 - carlsbad, calif. , nov. 7, 2024 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, today reported financial results for the quarter ended september 30, 2024, and highlighted recent corporate progress.
TYRA Ratings Summary
TYRA Quant Ranking